Roche's Alecensa gets US FDA approval for adjuvant treatment for people with ALK─positive early─stage lung cancer
Roche announced today that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for adjuvant treatment following tumour resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumours …